Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Thomas CC Yau"'
Autor:
Ava Kwong, Kenneth Sh Chok, Simon Hy Tsang, Thomas Cc Yau, Albert Cy Chan, Tan To Cheung, Wing Chiu Dai, Chung Mau Lo
Publikováno v:
Hepatobiliarypancreatic diseases international : HBPD INT. 18(5)
Background Survival of patients with breast cancer liver metastasis is very poor. This study aimed to analyze the survival outcome of hepatectomy for this patient population. Methods From January 1995 to December 2014, 2522 patients with liver cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c95beead78e8f2d7de2eb64b1adaf2de
https://pubmed.ncbi.nlm.nih.gov/31474444
https://pubmed.ncbi.nlm.nih.gov/31474444
Autor:
Jimmy Yuen, William Fn Chan, Li Chen, Ronnie T.P. Poon, Roberta Wc Pang, Pierre Chan, Paul N.M. Cheng, Sheung Tat Fan, Thomas Cc Yau
Publikováno v:
Investigational New Drugs
Summary Background Hepatocellular carcinoma (HCC) cells are auxotrophic for arginine, depletion of which leads to tumour regression. The current study evaluated safety, pharmacokinetics (PK)/ pharmacodynamics (PD) parameters, and potential anti-tumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0bf47c4ac114ff5973ed0c16df1f37b
http://europepmc.org/articles/PMC3553413
http://europepmc.org/articles/PMC3553413
Autor:
Ariel Km, Chow, Thomas Cc, Yau, Lui, Ng, Andrew Cy, Chu, Wai-Lun, Law, Ronnie Tp, Poon, Roberta Wc, Pang
Publikováno v:
American journal of cancer research. 5(8)
Transarterial chemoembolization (TACE) is commonly used for the treatment of locally advanced hepatocellular carcinoma (HCC) by its dual effects of chemotherapy and ischemic hypoxia. However, one of the side effects of TACE is the introduction of hyp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a13b84e86c002a43b0ca5550df2e22d7
https://pubmed.ncbi.nlm.nih.gov/26396913
https://pubmed.ncbi.nlm.nih.gov/26396913
Publikováno v:
Hepatocellular Carcinoma-Clinical Research
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide resulting in between 250,000 to one million deaths per annum. It carries dismal prognosis and the number death is close to the incidence of disease owing to t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::144ee8b2223124af198f51ba5486a65f
http://www.intechopen.com/articles/show/title/systemic-management-of-advanced-hepatocellular-carcinoma-patients-the-role-of-multi-targeted-anti-an
http://www.intechopen.com/articles/show/title/systemic-management-of-advanced-hepatocellular-carcinoma-patients-the-role-of-multi-targeted-anti-an
Autor:
Thomas Cc Yau, Ronnie Tp Poon, C. Martin Curtis, Pei-Jer Chen, Pierre Chan, Jennifer Gauvin, Mohammed M. Dar, Philip S Murphy, J. P. Hodge, A. Benjamin Suttle
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 17(21)
Background: A phase I dose-escalating study of pazopanib was conducted to determine the maximum tolerated dose (MTD), pharmacokinetic/pharmacodynamic relationships, and clinical activity in patients with advanced hepatocellular carcinoma (HCC). Exper
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95e7bb7b237e7341870ebb77e8890211
https://pubmed.ncbi.nlm.nih.gov/21831954
https://pubmed.ncbi.nlm.nih.gov/21831954
Autor:
Ariel KM Chow, Nathan SM Cheng, Colin SC Lam, Lui Ng, Sunny KM Wong, Timothy MH Wan, Man, Johnny HW, Alvin HK Cheung, Thomas CC Yau, Jensen TC Poon, Wai-Lun Law, Roberta WC Pang
Publikováno v:
Molecular Cancer; 2015, Vol. 14 Issue 1, p1-26, 26p, 9 Graphs